Scarica l'app Stockscreener
24.40
2.05%
0.49
Precedente Chiudi:
$23.91
Aprire:
$24.35
Volume 24 ore:
282.58K
Relative Volume:
0.94
Capitalizzazione di mercato:
$617.30M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.94%
1M Prestazione:
+15.26%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.97
$25.60
Intervallo di 1 settimana:
$22.20
$25.60
Portata 52W:
$13.36
$25.60
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Nome
Lb Pharmaceuticals Inc
Settore
Industria
Telefono
917-450-6581
Indirizzo
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
24.40 | 604.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Roth Capital | Buy |
| 2025-10-06 | Iniziato | Leerink Partners | Outperform |
| 2025-10-06 | Iniziato | Piper Sandler | Overweight |
| 2025-10-06 | Iniziato | Stifel | Buy |
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
LB Pharmaceuticals to Participate in Upcoming March Investor Events - Bitget
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
LBRX SEC FilingsLB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc's (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - MarketBeat
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - Defense World
LBRX Technical Analysis & Stock Price Forecast - Intellectia AI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighHere's Why - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New LB Pharmaceuticals lawyer gets 140,000 stock options at $24.22 - Stock Titan
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
LB Pharmaceuticals stock rises on $100M financing - MSN
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Announces $100 Million Private Placement Financing - TipRanks
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug By Investing.com - Investing.com Australia
LB Pharmaceuticals initiates Phase 2 trial of LB-102 - Yahoo Finance
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 6.4%Time to Sell? - MarketBeat
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug - Investing.com
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program - Sahm
LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals appoints Minako Pazdera as general counsel By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials - Investing.com
LB Pharmaceuticals appoints Minako Pazdera as general counsel - Investing.com
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel - manilatimes.net
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 5.5%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 7.7%Time to Buy? - MarketBeat
Two new leaders at LB Pharmaceuticals receive stock options - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated at Roth Capital - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com Australia
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com South Africa
Lb Pharmaceuticals Inc Azioni (LBRX) Dati Finanziari
Non sono disponibili dati finanziari per Lb Pharmaceuticals Inc (LBRX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):